Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 435

1.

Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.

Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA.

JAMA. 2004 Sep 15;292(11):1317-25.

PMID:
15367553
2.

A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer.

Lord SJ, Lei W, Craft P, Cawson JN, Morris I, Walleser S, Griffiths A, Parker S, Houssami N.

Eur J Cancer. 2007 Sep;43(13):1905-17. Epub 2007 Aug 2. Review.

PMID:
17681781
3.

Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer.

Warner E, Plewes DB, Shumak RS, Catzavelos GC, Di Prospero LS, Yaffe MJ, Goel V, Ramsay E, Chart PL, Cole DE, Taylor GA, Cutrara M, Samuels TH, Murphy JP, Murphy JM, Narod SA.

J Clin Oncol. 2001 Aug 1;19(15):3524-31.

PMID:
11481359
5.

Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.

Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM.

JAMA. 2006 May 24;295(20):2374-84.

PMID:
16720823
6.

Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.

Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay EA, Warren RM, Hill KA, Hoogerbrugge N, Wasser MN, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJ, Klijn JG, Plewes DB, Leach MO, de Koning HJ.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1458-68. doi: 10.1158/1055-9965.EPI-11-1196. Epub 2012 Jun 28.

7.

MRI in the early detection of breast cancer in women with high genetic risk.

Trecate G, Vergnaghi D, Manoukian S, Bergonzi S, Scaperrotta G, Marchesini M, Ferranti C, Peissel B, Spatti G, Bohm S, Conti A, Costa C, Sporeni M, Podo F, Musumeci R.

Tumori. 2006 Nov-Dec;92(6):517-23.

PMID:
17260493
8.

Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer.

Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK.

Cancer. 2011 Sep 1;117(17):3900-7. doi: 10.1002/cncr.25971. Epub 2011 Mar 1.

9.

Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.

Fakkert IE, Jansen L, Meijer K, Kok T, Oosterwijk JC, Mourits MJ, de Bock GH.

Breast Cancer Res Treat. 2011 Aug;129(1):157-64. doi: 10.1007/s10549-011-1423-4. Epub 2011 Mar 4.

PMID:
21373873
10.

The attitudes of women with BRCA1 and BRCA2 mutations toward clinical breast examinations and breast self-examinations.

Spiegel TN, Hill KA, Warner E.

J Womens Health (Larchmt). 2009 Jul;18(7):1019-24. doi: 10.1089/jwh.2008.1076.

PMID:
20377375
11.

Breast cancer detection among Irish BRCA1 & BRCA2 mutation carriers: a population-based study.

Walsh EM, Farrell MP, Nolan C, Gallagher F, Clarke R, McCaffrey JA, Kennedy MJ, Barry M, Kell MR, Gallagher DJ.

Ir J Med Sci. 2016 Feb;185(1):189-94. doi: 10.1007/s11845-015-1267-8. Epub 2015 Feb 12.

PMID:
25673166
12.

Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study.

Warner E, Causer PA, Wong JW, Wright FC, Jong RA, Hill KA, Messner SJ, Yaffe MJ, Narod SA, Plewes DB.

Breast J. 2011 Jan-Feb;17(1):9-17. doi: 10.1111/j.1524-4741.2010.01018.x.

PMID:
21251121
13.

Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.

Cott Chubiz JE, Lee JM, Gilmore ME, Kong CY, Lowry KP, Halpern EF, McMahon PM, Ryan PD, Gazelle GS.

Cancer. 2013 Mar 15;119(6):1266-76. doi: 10.1002/cncr.27864. Epub 2012 Nov 26.

14.

Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial.

Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, König R, Tombach B, Leutner C, Rieber-Brambs A, Nordhoff D, Heindel W, Reiser M, Schild HH.

J Clin Oncol. 2010 Mar 20;28(9):1450-7. doi: 10.1200/JCO.2009.23.0839. Epub 2010 Feb 22.

PMID:
20177029
15.

Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.

Lowry KP, Lee JM, Kong CY, McMahon PM, Gilmore ME, Cott Chubiz JE, Pisano ED, Gatsonis C, Ryan PD, Ozanne EM, Gazelle GS.

Cancer. 2012 Apr 15;118(8):2021-30. doi: 10.1002/cncr.26424. Epub 2011 Sep 20. Erratum in: Cancer. 2012 Nov 1;118(21):5448.

16.

Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence.

Shah P, Rosen M, Stopfer J, Siegfried J, Kaltman R, Mason B, Armstrong K, Nathanson KL, Schnall M, Domchek SM.

Breast Cancer Res Treat. 2009 Dec;118(3):539-46. doi: 10.1007/s10549-009-0475-1. Epub 2009 Jul 17.

17.

Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.

Hartman AR, Daniel BL, Kurian AW, Mills MA, Nowels KW, Dirbas FM, Kingham KE, Chun NM, Herfkens RJ, Ford JM, Plevritis SK.

Cancer. 2004 Feb 1;100(3):479-89.

18.

Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.

Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA, Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB, Narod SA.

Br J Cancer. 2012 Jun 26;107(1):24-30. doi: 10.1038/bjc.2012.204. Epub 2012 May 15.

19.

Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer.

Riedl CC, Ponhold L, Flöry D, Weber M, Kroiss R, Wagner T, Fuchsjäger M, Helbich TH.

Clin Cancer Res. 2007 Oct 15;13(20):6144-52.

20.

Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.

Riedl CC, Luft N, Bernhart C, Weber M, Bernathova M, Tea MK, Rudas M, Singer CF, Helbich TH.

J Clin Oncol. 2015 Apr 1;33(10):1128-35. doi: 10.1200/JCO.2014.56.8626. Epub 2015 Feb 23.

PMID:
25713430

Supplemental Content

Support Center